CA3138145A1 - Anti-abeta vaccine therapy - Google Patents
Anti-abeta vaccine therapy Download PDFInfo
- Publication number
- CA3138145A1 CA3138145A1 CA3138145A CA3138145A CA3138145A1 CA 3138145 A1 CA3138145 A1 CA 3138145A1 CA 3138145 A CA3138145 A CA 3138145A CA 3138145 A CA3138145 A CA 3138145A CA 3138145 A1 CA3138145 A1 CA 3138145A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine composition
- liposomal vaccine
- disease
- administered
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810.1 | 2019-05-21 | ||
| EP19175810 | 2019-05-21 | ||
| EP19185593.1 | 2019-07-10 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20171549.7 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| EP20172205.5 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3138145A1 true CA3138145A1 (en) | 2020-11-26 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3138145A Pending CA3138145A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (enExample) |
| EP (1) | EP3972633A1 (enExample) |
| JP (1) | JP7701734B2 (enExample) |
| KR (1) | KR20220010552A (enExample) |
| CN (1) | CN113853214A (enExample) |
| AU (1) | AU2020277682A1 (enExample) |
| BR (1) | BR112021023209A2 (enExample) |
| CA (1) | CA3138145A1 (enExample) |
| CL (1) | CL2021003051A1 (enExample) |
| IL (1) | IL288252A (enExample) |
| MX (1) | MX2021014102A (enExample) |
| MY (1) | MY210394A (enExample) |
| SG (1) | SG11202112329RA (enExample) |
| TW (1) | TW202110425A (enExample) |
| WO (1) | WO2020234405A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021260193A1 (en) * | 2020-06-25 | 2021-12-30 | Medimmune Limited | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
| KR20250137159A (ko) * | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR101152557B1 (ko) * | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| HUE055739T2 (hu) * | 2009-03-18 | 2021-12-28 | Ac Immune Sa | Eljárás terápiás alkalmazásra |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| JP6027011B2 (ja) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| AU2019253193B2 (en) | 2018-04-10 | 2026-02-05 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
-
2020
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020234405A1 (en) | 2020-11-26 |
| TW202110425A (zh) | 2021-03-16 |
| EP3972633A1 (en) | 2022-03-30 |
| JP7701734B2 (ja) | 2025-07-02 |
| JP2022533422A (ja) | 2022-07-22 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
| KR20220010552A (ko) | 2022-01-25 |
| SG11202112329RA (en) | 2021-12-30 |
| BR112021023209A2 (pt) | 2022-01-18 |
| MX2021014102A (es) | 2022-02-11 |
| CN113853214A (zh) | 2021-12-28 |
| US20220226447A1 (en) | 2022-07-21 |
| MY210394A (en) | 2025-09-18 |
| IL288252A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Monsonego et al. | Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease | |
| JP5889529B2 (ja) | アミロイド原性疾患の処置 | |
| US12324855B2 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
| US20220226447A1 (en) | Anti-abeta vaccine therapy | |
| US20080248055A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| US9707284B2 (en) | Formulations of peptides and chloroquines for the treatment of pathogenic immune responses in immune mediated diseases | |
| WO2015165980A2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| EA049756B1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| HK40058406A (en) | Anti-abeta vaccine therapy | |
| US20080226668A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| KR102388363B1 (ko) | 알츠하이머병（ａｄ）의 치료 및 예방 | |
| US20050250691A1 (en) | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes | |
| EP4654990A1 (en) | Anti-abeta vaccine therapy | |
| US20250049900A1 (en) | Method of safe administration of tau phosphopeptide conjugate | |
| TW201712027A (zh) | 多肽組合物 | |
| WO2023004044A2 (en) | Compositions and methods for treating neurodegenerative diseases by inhibiting fsh | |
| SCHNABEL et al. | 274 End Results |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250415 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250415 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260413 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260414 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260414 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260423 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260423 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260423 |